Bacterial milieu and mucosal bacteria in ulcerative colitis
- PMID: 15669634
- DOI: 10.1002/0470090480.ch5
Bacterial milieu and mucosal bacteria in ulcerative colitis
Abstract
The aetiology of ulcerative colitis (UC) is unknown, but there is evidence that bacteria are needed for initiation and maintenance of the disease. A number of organisms have been associated with UC, but evidence for a specific transmissible agent is weak. Despite this, there is a good case for mucosal bacterial involvement, either through pathogens colonizing the epithelial surface, by non-pathogenic commensal species occupying adhesion sites on the mucosa and preventing invasion by harmful bacteria, or by inappropriate host immune responses to members of the normal microflora. Since mucosal bacteria exist in close juxtaposition to host tissues, it might be expected that they interact to a greater extent with the immune and neuroendocrine systems than their luminal counterparts. For this reason, comparative bacteriological analyses were done on rectal biopsies from patients with active colitis, and individuals who had no inflammatory bowel disease. Complex bacterial communities colonized the rectal mucosa in all subjects and great interindividual variabilities in mucosal bacterial populations were observed in both groups. These organisms often occurred in microcolonies, which may have implications for UC, since it would result in higher localized concentrations of bacterial antigens, or toxins, than would be the case if the organisms were diffusely spread across the mucosa.
Similar articles
-
Chemotaxonomic analysis of bacterial populations colonizing the rectal mucosa in patients with ulcerative colitis.Clin Infect Dis. 2004 Jun 15;38(12):1690-9. doi: 10.1086/420823. Epub 2004 May 25. Clin Infect Dis. 2004. PMID: 15227614
-
Mucosal bacteria in ulcerative colitis.Br J Nutr. 2005 Apr;93 Suppl 1:S67-72. doi: 10.1079/bjn20041347. Br J Nutr. 2005. PMID: 15877898
-
Intestinal bacteria and ulcerative colitis.Curr Issues Intest Microbiol. 2003 Mar;4(1):9-20. Curr Issues Intest Microbiol. 2003. PMID: 12691258 Review.
-
Systemic antibodies towards mucosal bacteria in ulcerative colitis and Crohn's disease differentially activate the innate immune response.Gut. 2004 Jan;53(1):91-8. doi: 10.1136/gut.53.1.91. Gut. 2004. PMID: 14684582 Free PMC article.
-
Cellular and molecular immunopathogenesis of ulcerative colitis.Cell Mol Immunol. 2006 Feb;3(1):35-40. Cell Mol Immunol. 2006. Retraction in: Cell Mol Immunol. 2014 May;11(3):314. doi: 10.1038/cmi.2014.18. PMID: 16549047 Retracted. Review.
Cited by
-
Bacillus subtilis-mediated protection from Citrobacter rodentium-associated enteric disease requires espH and functional flagella.Infect Immun. 2012 Feb;80(2):710-9. doi: 10.1128/IAI.05843-11. Epub 2011 Dec 5. Infect Immun. 2012. PMID: 22144475 Free PMC article.
-
BVES is required for maintenance of colonic epithelial integrity in experimental colitis by modifying intestinal permeability.Mucosal Immunol. 2018 Sep;11(5):1363-1374. doi: 10.1038/s41385-018-0043-2. Epub 2018 Jun 15. Mucosal Immunol. 2018. PMID: 29907869 Free PMC article.
-
Probiotic Pre-treatment Reduces Gliclazide Permeation (ex vivo) in Healthy Rats but Increases It in Diabetic Rats to the Level Seen in Untreated Healthy Rats.Arch Drug Inf. 2008 Jul;1(1):35-41. doi: 10.1111/j.1753-5174.2008.00006.x. Arch Drug Inf. 2008. PMID: 20157366 Free PMC article.
-
The role of bacteria in the pathogenesis of inflammatory bowel disease.Gut Liver. 2010 Sep;4(3):295-306. doi: 10.5009/gnl.2010.4.3.295. Epub 2010 Sep 24. Gut Liver. 2010. PMID: 20981205 Free PMC article.
-
Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis.World J Gastroenterol. 2015 May 21;21(19):5985-94. doi: 10.3748/wjg.v21.i19.5985. World J Gastroenterol. 2015. PMID: 26019464 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical